Cadila Healthcare Gets USFDA Final Approval For Mesalamine Tablets

Cadila Healthcare on Wednesday announced that USFDA has given final approval to market Mesalamine Delayed-Released tablets USP, 1.2g in the US market. Zydus Cadila was the first to file an ANDA for a generic version of Lialda (mesalamine).

Lialda is used for the treatment of mild to moderate ulcerative colitis. Ulcerative colitis is a chronic inflammatory bowel disease that affects approximately 700,000 people in the United States. The generic version of Lialda (mesalamine) will be produced at Moraiya Plant located at Ahmedabad. The estimated brand sale for Mesalamine Delayed-Release tablets USP, 1.2g is USD 1.145 billion as per IMS MAT April 2017.

The group now has more than 115 approvals and has so far filler over 300 ANDAs since the commencement of the filling process in FY 2003-2004.

For Quick Trial – 8962000225 ✔ 
or mail us here:
or visit
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.